The iminosugar N-(5′-adamantane-1′-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-
DNM), an inhibitor of glycosphingolipid (GSL) biosynthesis is known to ameliorate diabetes …

Steatosis in the liver is a common feature of obesity and type 2 diabetes and the precursor to
the development of nonalcoholic steatohepatitis (NASH), cirrhosis, and liver failure. It has …

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and
type 2 diabetes. The hyperinsulinemia that occurs as a consequence of insulin resistance is …

Recent reports indicate that glycosphingolipids play an important role in regulation of
carbohydrate metabolism. We have shown that the iminosugar N‐(5′‐adamantane‐1′‐yl …

Objective—The iminosugar N-(5′-adamantane-1′-yl-methoxy)-pentyl-1-deoxynoijirimycin
(AMP-DNM), an inhibitor of the enzyme glucosylceramide synthase catalyzing …

The lipophilic iminosugar N-[5-(adamantan-1-ylmethoxy) pentyl]-1-deoxynojirimycin (2, AMP-
DNM) potently controls hyperglycemia in obese rodent models of insulin resistance. The …

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of metabolic
abnormalities ranging from simple hepatic steatosis (accumulation of neutral lipid) to …

Background Obesity is characterized by the accumulation of fat in the liver and other tissues,
leading to insulin resistance. We have previously shown that a specific inhibitor of …

Recent findings have implicated glycosphingolipids as modulators of insulin receptor
activity. Studies with C57BL/6J ob/ob mice have shown that insulin sensitivity is enhanced …

Metabolic associated fatty liver disease (MAFLD) has become one of the most common
causes of chronic liver disease and cirrhosis in the United States and around the world. 1–3 …